High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Wang, Xiaoen ^a   Zhang, Liang ^a   Goldberg, S Nahum ^a,b   Bhasin, Manoj ^a   Brown, Victoria ^c   Alsop, David C ^a   Signoretti, Sabina ^c   Mier, James W ^a   Atkins, Michael B ^a   Bhatt, Rupal S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anti angiogenic therapy; Arterial spin labeled magnetic resonance imaging; Renal cell carcinoma

Indexed keywords

SORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTIGRAPHY; SPIN LABELING; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT; ANIMAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; FEMALE; KIDNEY TUMOR; MICROVASCULATURE; NUDE MOUSE; PATHOLOGY; PERFUSION; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MICROVESSELS; PERFUSION; PYRIDINES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83755173977     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-220     Document Type: Article

References (24)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318. 10.1200/JCO.2008.19.5511, 19451442.
2. Amato RJ, Harris P, Dalton M, Khan M, Alter R, Zhai Q, Brady JR, Jac J, Hauke R, Srinivas S. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). [abstract]. J Clin Oncol 2007, 25(18S (June 20 Supplement)):5026.
3. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371. 10.1007/s00280-009-1170-y, 19967539.
4. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773. 10.1093/jnci/djr128, 3086879, 21527770.
5. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011, 17:3841-3849. 10.1158/1078-0432.CCR-10-2806, 21531811.
6. Albiges L, Salem M, Rini B, Escudier B. Vascluar endothelial growth factor targeted therapies in advanced renal cell carcinoma. Hematology/Oncology Clinics of North America: Renal Cell Cancer 2011, 25(4):813-833. Philadelphia: WB Saunders Company, Choueiri T.
7. Cho DC, Atkins MB. Future directions in renal cell carcinoma: 2011 and beyond. Hematology/Oncology Clinics of North America: Renal Cell Cancer 2011, 25(4):917-935. Philadelphia: WB Saunders Company, Choueiri T.
8. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1280-1289. 10.1200/JCO.2008.19.3342, 19171708.
9. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4462-8. 10.1200/JCO.2008.21.7034, 19652060.
10. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4068-4075. 10.1200/JCO.2008.20.5476, 19652072.
11. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial [abstract]. J Clin Oncol 2011, (suppl 7). abstr LBA308.
12. Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN. Does arterial spin labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. Radiology 2009, 251:731-742. 10.1148/radiol.2521081059, 2687534, 19474376.
13. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010, 9:2793-2802. 10.1158/1535-7163.MCT-10-0477, 2956167, 20699227.
14. Nexavar® [package insert]. 2006, Leverkusen, Germany: Bayer Pharmaceuticals Corp.
15. Wilhelm SM, Carter C, Tang L Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
16. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007, 59:561-574. 10.1007/s00280-006-0393-4, 17160391.
17. Alsop DC, Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 1996, 16:1236-1249.
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
19. Nosov D, Bhargava P, Esteves WB, Strahs AL, Lipatov ON, Lyulko OO, Anischenko AO, Chacko RT, Doval D, Slichenmyer WJ. Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). J Clin Oncol 2011, 29:s4550.
20. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068. 10.1200/JCO.2009.23.9764, 20100962.
21. Rini BI, Escudier B, Tomczak P, Kaprin A, Hutson TE, Szczylik C, Tarazi JC, Rosbrook B, Kim S, Motzer RJ. Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase 3 AXIS trial. J Clin Oncol 2011, 29:s4503.
22. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One 2011, 6:e19144. 10.1371/journal.pone.0019144, 3084751, 21559452.
23. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, Ramaiya N, Michaelson MD, Garcia JA, Knox JJ, Escudier B, Rini BI. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010, 116:5400-5406. 10.1002/cncr.25583, 21105118.
24. Gore ME, Jones RJ, Ravaud A, Kuczyk M, Demkow T, Bearz A, Laferriere N, Strauss UP, Porta C. Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment of metastatic renal cell carcinoma (RCC). J Clin Oncol 2011, 29:s4609.